TRACER

Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

Retrieved on: 
星期一, 四月 22, 2024
TRACER, Histology, Mouse, Phenotype, Data science, Cell, AAV, CNS, Machine learning, Senior, Tauopathy, Gene, Process, Society, BBB, ALS, Central nervous system, Public, HEK293, Therapy, Centrifuge, SOD1, Vaccine

“Voyager’s novel TRACER-derived capsids underlie 13 partnered programs and three wholly-owned programs to enable IV-delivery of gene therapies for diseases of the central nervous system.

Key Points: 
  • “Voyager’s novel TRACER-derived capsids underlie 13 partnered programs and three wholly-owned programs to enable IV-delivery of gene therapies for diseases of the central nervous system.
  • Three of those programs now have development candidates selected, and we see the potential for them to enter clinical trials next year,” said Todd Carter, Ph.D., Chief Scientific Officer of Voyager Therapeutics.
  • ET
    Intravenous administration of BBB-penetrant, MAPT-Silencing, AAV gene therapy provides broad and robust CNS Tau lowering in tauopathy mouse models (#1602).
  • ET
    Intravenous delivery of AAV gene therapy for the treatment of SOD1-ALS provides broad SOD1 lowering in NHP (#1647).

Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

Retrieved on: 
星期二, 四月 16, 2024
FDA, TRACER, Neurocrine Biosciences, Traffic barrier, Neurocrine, Research, Sympathetic nervous system, AAV, IND, GBA1, DSM-IV codes, FA, Clinical trial, Therapy, Investigational New Drug, SOD1, Pharmaceutical industry

The candidate combines a GBA1 gene replacement payload with an intravenously administered, blood-brain barrier penetrant, novel capsid derived from Voyager’s TRACER™ capsid discovery platform.

Key Points: 
  • The candidate combines a GBA1 gene replacement payload with an intravenously administered, blood-brain barrier penetrant, novel capsid derived from Voyager’s TRACER™ capsid discovery platform.
  • Selection of the development candidate triggered a $3 million milestone payment to Voyager, which the Company expects to receive in the second quarter of 2024.
  • Voyager is eligible to receive additional future development and commercialization milestone payments based on the further advancement of this program.
  • “The nomination of this development candidate in the GBA1 program, following the recent nomination of a development candidate in the Friedreich’s ataxia program, demonstrates the productivity of the collaboration between Voyager and Neurocrine to advance gene therapies for neurological diseases,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager.

Astrotech Announces Listing to the GSA as an Approved United States Government Vendor

Retrieved on: 
星期一, 四月 8, 2024
Astrotech, SDVOSB, Conference, Transport, ETD, Intelligence, Knowledge, NTD, Aviation, European Civil Aviation Conference, Small business, GSA, Mass spectrometry, TSA, ASTC, TRACER

AUSTIN, Texas, April 08, 2024 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ: ASTC) ("Astrotech" or the "Company") and its wholly owned subsidiary, 1st Detect Corporation (1st Detect), announce that 1st Detect’s TRACER 1000TM is now listed in the U.S. General Services Administration (GSA) IT Schedule 70 under Contract No. GS-35F-250GA with SRI Group LLC, Special Item Number 334290.   IT Schedule 70 is a long-term contract issued by the GSA to commercial technology vendors that allows sales to the U. S. federal government, one of the largest buyers of goods and services in the world. GSA’s thorough evaluation determined that 1st Detect’s pricing is fair and reasonable, that 1st Detect had the requisite capabilities, organizational structure, customer satisfaction and performance history, and that the offered products and services are compliant with applicable laws and regulations.

Key Points: 
  • IT Schedule 70 is a long-term contract issued by the GSA to commercial technology vendors that allows sales to the U. S. federal government, one of the largest buyers of goods and services in the world.
  • The TRACER 1000 maintains the accuracy of much larger mass spectrometers even though it is only the size of a desktop printer.
  • The Astrotech Mass Spectrometer Technology™ drives the breakthrough TRACER 1000, as the first certified ETD to employ mass spectrometry.
  • 1st Detect has engaged with SRI Group LLC, a distinguished GSA provider led by retired Deputy Administrator of the Transportation Security Administration (TSA) John Halinski.

Astrotech to Showcase the Tracer 1000 Trace Detector at ISC West Conference

Retrieved on: 
星期二, 四月 2, 2024
Narcotic, Certification, Astrotech, Conference, Heroin, Cocaine, ETD, International, Law enforcement, NTD, Prison, European Civil Aviation Conference, Exposition, Astrotech Corporation, Airport, Mass spectrometry, ASTC, TRACER, Fentanyl, Drug

The TRACER 1000 is a high-performance laboratory instrument that is powered by the Astrotech Mass Spectrometer Technology™ (“AMS Technology”).

Key Points: 
  • The TRACER 1000 is a high-performance laboratory instrument that is powered by the Astrotech Mass Spectrometer Technology™ (“AMS Technology”).
  • Currently, the Company’s Tracer 1000 ETD is now found in multiple locations in 14 countries throughout the world.
  • “We are extremely excited to share our user-friendly mass spectrometer the TRACER 1000, which is powered by our AMS Technology, with leading industry experts and security industry professionals at the ISC West conference.
  • The TRACER 1000 is the first mass spectrometry-based ETD to have received European Civil Aviation Conference (“ECAC”) certification for both checkpoint and cargo security.

Astrotech Introduces the “Gold Standard” of Mass Spectrometry into Narcotics Detection Market with its State-of-the-Art Tracer 1000

Retrieved on: 
星期一, 三月 25, 2024
Astrotech, Conference, Heroin, Cocaine, ETD, Law enforcement, NTD, Prison, European Civil Aviation Conference, Airport, Mass spectrometry, ASTC, TRACER, Fentanyl, Drug

The TRACER 1000 NTD is a high-performance laboratory instrument capable of rapid detection of trace levels of narcotic compounds in seconds.

Key Points: 
  • The TRACER 1000 NTD is a high-performance laboratory instrument capable of rapid detection of trace levels of narcotic compounds in seconds.
  • Currently, the Company’s Tracer 1000 Explosive Trace Detector (ETD) is now found in multiple locations in 14 countries throughout the world.
  • The Astrotech Mass Spectrometer Technology™ (AMS Technology) drives the breakthrough TRACER 1000, as the first certified ETD to employ mass spectrometry as a trace detection security solution.
  • The TRACER 1000 is the only mass spectrometry-based ETD to have received European Civil Aviation Conference certification for both checkpoint and cargo security.

Allied Instrumentation Expands Reach as nVent RAYCHEM Representative

Retrieved on: 
星期五, 二月 23, 2024
Acquisition, Great Lakes region, Natural gas, TRACER, Food, MRO

RIVERDALE, Iowa, Feb. 23, 2024 /PRNewswire-PRWeb/ -- Allied Instrumentation continues its legacy as a leading nVent RAYCHEM representative and stocking distributor, serving E. Missouri, Illinois, W. Kentucky, and the Indiana counties of Lake, Porter, and LaPorte for over 50 years. Recently, Allied has bolstered its presence by acquiring the assets of Dale Prentice Company in the Great Lakes region, expanding its coverage to include Michigan and Eastern Wisconsin.

Key Points: 
  • With the acquisition of the assets of Dale Prentice Company, Allied Instrumentation solidifies its position as an exclusive industrial representative for nVent RAYCHEM by expanding their coverage to include Michigan and Eastern Wisconsin.
  • RIVERDALE, Iowa, Feb. 23, 2024 /PRNewswire-PRWeb/ -- Allied Instrumentation continues its legacy as a leading nVent RAYCHEM representative and stocking distributor, serving E. Missouri, Illinois, W. Kentucky, and the Indiana counties of Lake, Porter, and LaPorte for over 50 years.
  • With this strategic move, Allied Instrumentation solidifies its position as the exclusive industrial representative for nVent RAYCHEM solutions in the region.
  • Leveraging their expertise and commitment to customer satisfaction, Allied Instrumentation offers comprehensive support for nVent RAYCHEM heat management solutions, including sales, designs, takeoffs, and MRO activity.

Astrotech Reports Second Quarter Of Fiscal Year 2024 Financial Results

Retrieved on: 
星期一, 二月 12, 2024
Acquisition, Astrotech Corporation, ECAC, Traction, Air cargo, Growth, Airport, ASTC, IMS, European, TRACER, ETD, TSA, Salvinia minima, Transport, Research

AUSTIN, Texas, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for the second quarter of fiscal year 2024, which ended December 31, 2023.

Key Points: 
  • AUSTIN, Texas, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for the second quarter of fiscal year 2024, which ended December 31, 2023.
  • Year-to-date fiscal year 2024 gross margin increased to 46% from 38% during the comparative period in the prior year, as we continue to benefit from the further refining and ruggedizing of our equipment.
  • After the end of the quarter, 1st Detect reentered detection and non-detection testing with the U.S. Transportation Security Administration (TSA) for cargo security.
  • We exhibited it at this year’s MJ BizCon held late in the second quarter of fiscal year 2024.

IBN Coverage Initiated for Astrotech Corp.

Retrieved on: 
星期三, 一月 17, 2024
ASTC, Astrotech, Social media, Agriculture, ECAC, TRACER, ATI Technologies, IBN, Airport, ETD, Certification

Through its Astrotech Technology Inc. (ATi) subsidiary, Astrotech owns and licenses proprietary mass spectrometry solutions for a variety of industries and applications.

Key Points: 
  • Through its Astrotech Technology Inc. (ATi) subsidiary, Astrotech owns and licenses proprietary mass spectrometry solutions for a variety of industries and applications.
  • Other applications for the company’s technology include AgLAB-1000, a process control system, and the BreathTest 1000, a disease detection solution.
  • Astrotech also announced the creation of its newest wholly owned subsidiary, Pro-Control Inc., which has an exclusive ATi field-of-use license for worldwide chemical manufacturing and process control applications.
  • IBN is uniquely positioned to provide Astrotech the solutions needed to reach a wide audience of investors, journalists and the general public.

Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies

Retrieved on: 
星期二, 一月 2, 2024
Spinal muscular atrophy, NVS, HD, Therapy, TRACER, DSM-IV codes, Biomedical Research, Biomedicine, Central nervous system, Patient, SMA, Pharmaceutical industry

LEXINGTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS) to advance potential gene therapies for Huntington’s disease (HD) and spinal muscular atrophy (SMA). Voyager will provide Novartis a target-exclusive license to access Voyager’s TRACER™ capsids and other intellectual property for the respective diseases, and Voyager and Novartis will collaborate to advance a preclinical gene therapy candidate for HD.

Key Points: 
  • LEXINGTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS) to advance potential gene therapies for Huntington’s disease (HD) and spinal muscular atrophy (SMA).
  • Voyager will provide Novartis a target-exclusive license to access Voyager’s TRACER™ capsids and other intellectual property for the respective diseases, and Voyager and Novartis will collaborate to advance a preclinical gene therapy candidate for HD.
  • “We are thrilled to expand our existing relationship with Novartis, a global leader in the gene therapy field,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager.
  • Novartis will also receive worldwide rights to Voyager’s AAV gene therapy for HD, leveraging Voyager’s TRACER capsids and proprietary payloads.

Astrotech Reports First Quarter of Fiscal Year 2024 Financial Results

Retrieved on: 
星期一, 十一月 13, 2023
Acquisition, Research, Audit committee, THC, LLP, TRACER, Telecommunications, Air cargo, Salvinia minima, Transportation Security Administration, Cannabis, Explosives trace detector, Astrotech Corporation, Transport, ASTC, European, Letter, TSA, CBD

AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for the first quarter of fiscal year 2024, which ended September 30, 2023.

Key Points: 
  • AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for the first quarter of fiscal year 2024, which ended September 30, 2023.
  • Gross margin improved to 43% for the first quarter of fiscal year 2024, compared to 16% in the first quarter of the fiscal year 2023.
  • An engagement letter with RBSM was executed on October 12, 2023, for the appointment for the fiscal year ended June 30, 2024.
  • This is a significant improvement in cannabinoid oil processing yields and adds to our potential customer’s bottom line.” stated Thomas B. Pickens, III.